Orthofix Medical (OFIX) Research & Development (2010 - 2026)

Orthofix Medical's Research & Development history runs 17 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• Quarterly Research & Development fell 22.49% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.4 million (down 16.93% YoY) and the FY2025 annual result came in at $65.8 million, down 10.59% from the prior year.
• Research & Development was $15.3 million for Q1 2026 at Orthofix Medical, roughly flat from $15.4 million in the prior quarter.
• Across five years, Research & Development topped out at $99.2 million in Q2 2023 and bottomed at -$207.8 million in Q4 2023.
• A 5-year average of $7.5 million and a median of $17.3 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development soared 695.0% — and 2024, when it plunged 81.81%.
• Orthofix Medical's Research & Development stood at -$120.4 million in 2022, then tumbled by 72.52% to -$207.8 million in 2023, then surged by 109.05% to $18.8 million in 2024, then dropped by 18.26% to $15.4 million in 2025, then dropped by 0.34% to $15.3 million in 2026.
• Business Quant data shows OFIX's Research & Development at $15.3 million in Q1 2026, $15.4 million in Q4 2025, and $14.8 million in Q3 2025.